A 53-year-old woman diagnosed with
rheumatoid arthritis (RA) demonstrated thick-walled large cavities with consolidation in the left upper lobe on chest computed tomography (CT). Mycobacterium avium was isolated from sputum cultures, and she was diagnosed as having the fibrocavitary (FC) form of pulmonary Mycobacterium avium complex (MAC) disease.
Clarithromycin-containing, multidrug, anti-MAC
chemotherapy was started immediately. After 7 months, the cavitary lesions improved, and sputum cultures showed negative conversion. Thereafter,
abatacept monotherapy was started due to high RA disease activity. Clinical remission of RA has been sustained and cavitary lesions disappeared by concomitant
abatacept and anti-MAC
therapy for more than 5 years. Immediate initiation of anti-MAC
therapy and prior confirmed efficacy are needed for the treatment of the FC form.
Abatacept and anti-MAC
therapy could be continued, leading to the withdrawal of
prednisolone, along with careful observation by strict chest CT evaluation and repeated sputum cultures. Biologics are generally contraindicated for pulmonary MAC disease, particularly the FC form. When there is a pre-existing lung lesion apparently of FC type,
abatacept cannot be started without prior anti-MAC
chemotherapy. This case suggests that
abatacept may be carefully used to avoid progressive joint destruction after FC lesions of pulmonary MAC disease are resolved.